The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer

BMC Cancer

Table 1 Clinicopathological characteristics of ER-positive breast cancer patient cohorts

	Predictive Endocrine Therapy Cohorts		Prognostic Cohort
	Tamoxifen	Aromatase inhibitors	Lymph node negative (LNN)
Total	235	87	279
Median age (range)	61 (29–90)	66 (35–86)	55 (26–85)
Menopausal Status:
Premenopausal	60	4	120
Postmenopausal	175	82	159
Surgery:
Lumpectomy	87	8	178
Ablation	147	22	101
Adjuvant hormonal therapy:
no	235	17	279
yes	0	69	0
Adjuvant chemotherapy:
no	198	69	279
yes	37	18	0
Lymph node status:
negative	102	20	279
positive	81	49	0
not applicable (M1)	42	17	0
Distant metastasis:
yes	235	87	165
no	0	0	114
Disease -Free Interval:
< 1 year	59	13	20
1–3 year	108	29	71
> 3 year	68	45	188
Median Follow-up time (in months):
after surgery	62 (3–272)	103 (7–295)	93 (5–337)
after start therapy	30 (1–208)	45 (2–108)
PR status^a:
Positive	186	72	217
Negative	48	15	62
HER2 status^a:
Amplified	31	10	43
Not amplified	202	77	233
CCDC170 status^a:
Positive	206	81	252
Negative	28	3	26

ESR1 estrogen receptor alpha, LNN lymph node negative disease, M1 methastatic stage 1, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, CCDC170 coiled-coil domain containing 170, RT-qPCR Quantitative Real-Time Polymerase Chain Reaction
^aas measured by RT-qPCR

ISSN: 1471-2407